Medical devices suppliers conducting agreements for allowing hospitals to use free of charge their equipment might face both VAT and corporate tax adverse implications.Continue reading Cutting edge tax implications for medical devices suppliers in Europe
Innovation gilt als Kernwert des Wirtschaftsstandorts Schweiz – und der MedTech-Branche. Das Volks-Ja zur Steuerreform hat der innovativen Tätigkeit von Unternehmen wie Ihrem eine neue Bedeutung verliehen. Auch andere nationale und internationale Neuerungen der indirekten Steuern und Zölle sowie neue regulatorische Rahmenbedingungen wirken sich 2020 auf die aktuelle und zukünftige Situation Ihres Unternehmens aus.
Wie daraus ein echter Mehrwert generiert werden kann, möchten wir gerne an unserem speziell der MedTech Branche gewidmeten Event mit Ihnen diskutieren.Continue reading Event: “Tax Engineering” für MedTech – 19. März 2020, PwC Luzern
1. The background in a nutshell
- Until 25th May 2020 all Medtech products that are admitted in Switzerland for the sale can be distributed also in the EU.
- However, currently a new treaty is negotiated by Switzerland and the EU Joint Committee in that regard.
- In case the treaty is not going to be concluded between Switzerland and the EU, all Medtech companies based in Switzerland are considered as not being anymore part of the EU. Indeed this treaty hangs by a hair.
Following the latest developments of the Swiss-EU negotiations concerning the Institutional Agreement and the Mutual Recognition Agreement (MRA), Swiss Medtech companies should be preparing for the case in which MRA would no longer apply to the medical devices after 26th May 2020.Continue reading Swiss Medtech companies – action required for the sale of products in the EU as per May 2020 – Is your business ready for the upcoming changes?
On November 15, in Lugano we have been honored to host the annual Tax Forum, which represents for PwC the main tax event in the Ticino area. This year we had the pleasure to host, as guest speaker, the Federal Councilor Ignazio Cassis, head of the Federal Department of Foreign Affairs.Continue reading Pharma & Life Sciences – The future is now: from digitalization in tax to AVIS28
I would like to invite you to our next webinar “Pharma & VAT Quick Fixes – Exploring the Right Formula which will be held on 8 November 2019 from 9:00am to 10:00am and from 3.00pm to 4.00pm.Continue reading Webinar: Pharma & VAT Quick Fixes – Exploring the Right Formula
Why should you as a pharma & life sciences company register to the event?
- you will gathering insights on relevant topics of the Swiss VAT authorities – directly from the competent officer of the Federal Tax Administration (FTA)
- you strive to be prepared as per 1 January 2020 regarding the EU VAT Quick Fixes and its implications e.g. for pharma & life sciences companies
I hope you had a relaxing summer time.
Do you face troubles in order to be up to date with all the required legislation changes in various countries in the Regulatory Pharma & Life Sciences field AND combine it with your supply chain and tax strategy?
I am happy to inform you that we have recently launched our Pharma & Life Sciences Regulatory Radar, to strive to assist you in that regard.Continue reading Cutting Edge Digital Solution – Pharma & Life Sciences Regulatory Radar
Recently you received a lot information related to Brexit. The key question in that regard: what is the next most favorable step for your Pharma and Life Sciences business? The center of the discussion should still be the handling of your supply chain.
Please find hereinafter some inputs in that regard from an UK, Ireland and Swiss perspective for your convenience:
Do you perform Clinical Trials in Europe and are want to be informed of the respective VAT consequences?
Together with my Pharma VAT colleagues from PwC I collected the data and organised for the set up of the PwC “VAT Guide to Clinical Trials in Europe”.
I am pleased to invite you to have a closer look at the countries of your interest:Continue reading A Guide to VAT for Clinical Trials through Europe
Hope you had a good start into 2019.
As you may already gathered through the press the referendum for the Swiss Tax Bill and AHV-Financing (Steuervorlage und AHV-Finanzierung – STAF) has been launched with success.
The respective popular vote will take place in spring, i.e. on 19 May 2019.
A lot of pharma and life sciences companies are currently dealing with the question what will STAF mean for them.
- Introduction of patent box – mandatory at cantonal level
- Introduction of the special deduction for R&D costs – optional for the cantons (this deduction may not exceed 50% of the relevant R&D expenditure in Switzerland)
Tax advantages for income from patents/intellectual rights are intended to promote research and development activities and corresponding value creation. The legislation text defines which patents or comparable rights qualify for patent box taxation. In accordance with the international OECD standard, the Nexus approach will apply either by patent, by product or by product family.
For further details please contact Armin Marti or me via the usual way.
Partner & Leader Tax Policy ,
Zurich, PWC Switzerland
+41 58 792 43 43